In agreement with these findings, in our study, we observed that AZD1775 treatment indeed led to an increase in cell apoptosis in ESCC cells, as demonstrated by a dose- and time-dependent increase in annexin-V-binding cells and upregulation of cleaved PARP and caspase-3. Here, ANXA5 is linked to esophageal squamous cell carcinoma.